Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Novartis Ag (NVSEF) Equity Income (2016 - 2025)

Historic Equity Income for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to -$2.0 million.

  • Novartis Ag's Equity Income rose 3333.33% to -$2.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$12.0 million, marking a year-over-year increase of 6842.11%. This contributed to the annual value of -$12.0 million for FY2025, which is 6842.11% up from last year.
  • Latest data reveals that Novartis Ag reported Equity Income of -$2.0 million as of Q4 2025, which was up 3333.33% from -$4.0 million recorded in Q3 2025.
  • In the past 5 years, Novartis Ag's Equity Income registered a high of $14.6 billion during Q4 2021, and its lowest value of -$29.0 million during Q1 2024.
  • In the last 5 years, Novartis Ag's Equity Income had a median value of -$3.0 million in 2022 and averaged $803.5 million.
  • In the last 5 years, Novartis Ag's Equity Income surged by 1026950.35% in 2021 and then plummeted by 135000.0% in 2024.
  • Novartis Ag's Equity Income (Quarter) stood at $14.6 billion in 2021, then crashed by 100.02% to -$3.0 million in 2022, then crashed by 100.0% to -$6.0 million in 2023, then skyrocketed by 50.0% to -$3.0 million in 2024, then surged by 33.33% to -$2.0 million in 2025.
  • Its Equity Income stands at -$2.0 million for Q4 2025, versus -$4.0 million for Q3 2025 and -$3.0 million for Q2 2025.